Investing.com — Dyne Therapeutics, a biotechnology firm, noticed its shares rise by as much as 10% after the market closed on Wednesday.
The surge in inventory value got here as the corporate introduced an investor convention name to overview new medical information.
The info is from its ACHIEVE trial, a examine specializing in a but undisclosed remedy. The corporate has not supplied additional particulars on the character of the trial or the info to be reviewed.
Dyne Therapeutics, which makes a speciality of creating therapies for sufferers with critical muscle illnesses, mentioned the overview of the info is scheduled for January 10.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.
Donald Trump has usually mentioned that his "favorite phrase" is "tariff". Certainly 'deal' would are…
Thames Water chief govt Chris Weston has apologised to clients and promised to show the…
The chairman of the UK's greatest water firm has apologised to prospects however defended workers…
The way forward for Nissan's Sunderland operations is unsure because the Japanese automotive maker cuts…
Each Tuesday our Cash weblog group solutions your Cash Issues. You possibly can e-mail yours…
A start-up founder who leads a government-backed feminine entrepreneurship initiative is among the many contenders…